Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive Investors the Massachusetts-based company has landed its second major contract with an unnamed, multi-billion dollar pharmaceutical company to manufacture a candidate protein drug.
Schumacher says the deal utilizes Pressure’s BaroFold platform, which uses high pressure to modify protein drug samples, unfolding and refolding peptides, benefiting patients.
Price: 1.545 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil. Schumacher explains the company’s PCT...
Health
Retail & consumer
Prev article
